Bayesian Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Bayesian Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,013	Closed	-$1.09M	–	670
2024 Q2	$1.09M	Buy	+8,013	New	+$1.09M	0.13%	209
2024 Q1	–	Sell	-5,561	Closed	-$700K	–	773
2023 Q4	$700K	Buy	5,561 +2,432	+78%	+$242K	0.07%	311
2023 Q3	$293K	Buy	+3,129	New	+$293K	0.03%	474
2023 Q1	–	Sell	-6,500	Closed	-$794K	–	770
2022 Q4	$794K	Buy	6,500 +600	+10%	+$69.7K	0.12%	229
2022 Q3	$609K	Buy	5,900 +3,400	+136%	+$322K	0.12%	238
2022 Q2	$232K	Sell	2,500 -3,135	-56%	-$295K	0.04%	572
2022 Q1	$661K	Buy	+5,635	New	+$653K	0.1%	302

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bayesian Capital Management's ASND Position: Q3 2024 in Review

Bayesian Capital Management sold out of Ascendis Pharma A/S (ASND) in Q3 2024, closing a stake of 8,013 shares — an estimated $1.09M sold.

Bayesian Capital Management first reported a position in ASND in Q1 2022 and held it in 7 quarters. The position peaked at $1.09M in Q2 2024. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

Bayesian Capital Management reported no remaining Ascendis Pharma A/S position as of Q3 2024 after selling out during the quarter.
Bayesian Capital Management sold 8,013 Ascendis Pharma A/S shares in Q3 2024, an estimated $1.09M.
Bayesian Capital Management first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 7 quarters.
Bayesian Capital Management's Ascendis Pharma A/S position peaked at $1.09M in Q2 2024.
219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.